Personalized medicine
The life sciences company's Gut Intelligence Test will be available in 200 CVS locations and through the drugstore chain online.
The partnership will allow Molina's Virginia-based Medicare and healthcare marketplace members access to culturally competent maternal health experts.
The purchase comes on the heels of the surgical navigation platform's $82.5 million Series D raise in June.
The company will use the investment to fuel the expansion of Paradigm,its FDA-cleared, AI-enabled surgical navigation platform.
The multiple sclerosis-focused company will use the funds to speed up the company's commercialization efforts.
The Ohio-based company's XR90 offering allows physicians to view a patient's anatomical structures in 3D for preoperative and intraoperative use.
The funding comes three months after the company announced it added AI-enabled imaging features and new indications expanding xvision's use to the whole spine.
The company will use the funds to circulate its ArteraAI Prostate Test and to develop tests to support individualized therapy options for other cancers.
The funds will be used to expand its research and development teams in the U.S. and Israel.
Elena Viboch, partner at General Catalyst, discusses her predictions for biotech and health tech investing and how startups can grow in a more constrained economic environment.